It has been previously demonstrated that the enzymic activity of rat liver 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA reductase; EC 1.1.1.34) is modulated in vitro and in vivo by a bicyclic cascade system involvmg reversible phosphorylation of HMG-CoA reductase and reductase kinase. In the present study, administration of mevalonolactone to rats caused a rapid inhibition of HMGCoA reductase activity. The initial short-term (20-min) reversible inhibition (38%) of enzyme activity was due to increased phosphorylation of HMG-CoA reductase. The Inhibition of HMG-CoA reductase activity by increased phosphorylation was associated with an increased activity and phosphorylation (2-to 3-fold) of reductase kinase. The increased phosphorylation of reductase kinase was catalyzed by reductase kinase kinase, which was significantly elevated (3-to 4-fold) after the administration of mevalonolactone to rats. The mechanism for the in vivo activation of reductase kinase kinase is as yet unknown. Mevalonolactone administration was also associated with a significant inhibition of phosphoprotein phosphatase activity, which dephosphorylates both HMG-CoA reductase (activation) and reductase kinase (inactivation). These results indicate that mevalonolactone administration to rats in vivo was associated with an inhibition of HMG-CoA reductase activity by two mechanisms: (i) an increase in the degree of phosphorylation of both HMG-CoA reductase and reductase kinase due to increased activity of reductase kinase kinase; (ii) a decrease in the dephosphorylation of both HMG-CoA reductase and reductase kinase secondary to inhibition of phosphoprotein phosphatase activity. These combined effects favor an increase in the steady-state level of the phosphorylated forms of both HMG-CoA reductase and reductase kinase, resulting in a net reduction in the enzymic activity of HMG-CoA reductase and mevalonate formation. These results demonstrate that the activity of reductase kinase kinase is modulated in vivo, providing a mechanism for the regulation of the activities of both reductase kinase and HMG-CoA reductase.
ible inhibition (38%) of enzyme activity was due to increased phosphorylation of HMG-CoA reductase. The Inhibition of HMG-CoA reductase activity by increased phosphorylation was associated with an increased activity and phosphorylation (2-to 3-fold) of reductase kinase. The increased phosphorylation of reductase kinase was catalyzed by reductase kinase kinase, which was significantly elevated (3-to 4-fold) after the administration of mevalonolactone to rats. The mechanism for the in vivo activation of reductase kinase kinase is as yet unknown. Mevalonolactone administration was also associated with a significant inhibition of phosphoprotein phosphatase activity, which dephosphorylates both HMG-CoA reductase (activation) and reductase kinase (inactivation). These results indicate that mevalonolactone administration to rats in vivo was associated with an inhibition of HMG-CoA reductase activity by two mechanisms: (i) an increase in the degree of phosphorylation of both HMG-CoA reductase and reductase kinase due to increased activity of reductase kinase kinase; (ii) a decrease in the dephosphorylation of both HMG-CoA reductase and reductase kinase secondary to inhibition of phosphoprotein phosphatase activity. These combined effects favor an increase in the steady-state level of the phosphorylated forms of both HMG-CoA reductase and reductase kinase, resulting in a net reduction in the enzymic activity of HMG-CoA reductase and mevalonate formation. These results demonstrate that the activity of reductase kinase kinase is modulated in vivo, providing a mechanism for the regulation of the activities of both reductase kinase and HMG-CoA reductase.
3-Hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCoA reductase; EC 1.1.1.34) is the rate-limiting enzyme in the pathway for cholesterol biosynthesis (1) (2) (3) . The enzymic activity of rat liver HMG-CoA reductase is modulated in vitro by reversible phosphorylation (2, 3) . The ATP-dependent inactivation of HMG-CoA reductase is catalyzed by reductase kinase, and reactivation requires a cytosolic phosphatase. Reductase kinase activity is present in both microsomes and cytosol. Reductase kinase activity, like HMGCoA reductase, is also modulated by a phosphorylationdephosphorylation reaction sequence (2, 3) . The activation (phosphorylation) of reductase kinase is catalyzed by a second protein kinase, designated reductase kinase kinase. Dephosphorylation is catalyzed by a cytosolic reductase kinase phosphatase (2, 3) . Previous studies have established that both HMG-CoA reductase and reductase kinase activity are modulated in intact animals by glucagon (4) . In addition, both HMG-CoA reductase and reductase kinase are regulated in freshly isolated rat hepatocytes by glucagon and insulin (5) . To date, however, no data have been published describing the regulation of the activity of reductase kinase kinase in vitro or in vivo.
We have utilized mevalonolactone, an important obligatory intermediate in the biosynthesis of cholesterol, to investigate the mechanism(s) involved in the in vivo regulation of the activities of HMG-CoA reductase and reductase kinase. The administration of mevalonolactone to rats was associated with a biphasic inhibition of HMG-CoA reductase activity (6) (7) (8) . The first phase (20 min) of enzymic inhibition was due to reversible inactivation of HMG-CoA reductase. The second phase (60 min) of inhibition of enzyme activity was an irreversible process and independent of phosphorylation (6) (7) (8) . We have definitively established that the initial shortterm regulation of HMG-CoA reductase activity involves increased phosphorylation by demonstrating an increased incorporation of 32p into HMG-CoA reductase isolated from livers of rats treated with mevalonolactone (20 min) as compared to control rats (3, 8) . Erickson et al. (7) have reported that cytosol from mevalonolactone-treated rats had only 36% of the activator potency (in terms of HMG-CoA reductase reactivation) of control cytosol. In addition, incubation of hepatocytes in vitro with mevalonolactone has also been reported to cause 60% inactivation of cytosolic reductase phosphatase (9) .
In the present report, we have established that rat liver reductase kinase kinase is modulated in vivo after the administration of mevalonolactone. In addition, the short-term effect of mevalonolactone administration on the activity of phosphoprotein phosphatase, which catalyzes the dephosphorylation of reductase kinase (inactivation) and HMGCoA reductase (activation), was investigated. These studies provide evidence that the activity of reductase kinase kinase is regulated in vivo and that the modulation of the activity of both reductase kinase kinase and phosphoprotein phosphatase may exquisitely control the activities of reductase kinase and HMG-CoA reductase.
MATERIALS AND METHODS Chemicals. HMG-CoA, ATP, and NADPH were purchased from P-L Biochemicals; DL-mevalonic acid and its lactone were obtained from Sigma; [3- (2 weeks) and fed 3% cholestyramine for 6 days. Eleven rats in a control group were given 1.5 ml of water, whereas 12 rats received mevalonolactone (600 mg/ kg) by nasogastric tube. After 20 min of treatment rats were killed by decapitation, livers were excised, and microsomes were isolated (4) . HMG-CoA reductase from both the groups was solubilized and purified to homogeneity by HMG-CoA affinity chromatography as described (4) .
Isolation of Reductase Kinase-Free Microsomal HMG-CoA Reductase. The unwashed microsomal pellets obtained from control rats (chloride group) were suspended in a buffer containing 50 mM potassium phosphate at pH 7.2, 250 mM KCI, 2 mM dithiothreitol, and 10% (vol/vol) glycerol and incubated at 50°C for 15 min and then stored frozen at -80°C.
Isolation of Dephosphorylated (Inactive) Cytosolic and Microsomal Reductase Kinase. Cytosol (25.5 mg/ml) isolated with NaF was separated from low molecular weight contaminants by chromatography on a Sephadex G-25 medium column (1.5 x 5 cm) equilibrated in 50 mM imidazole HCl, pH 7.5/0.1 M sucrose/1 mM EDTA/0.25 M NaCl/2 mM dithiothreitol (buffer A). Aliquots of 0.2 ml of cytosol (16.5 mg/ml) were incubated with 0.2 ml of 0.5 M NaCl, 0.9 ml of partially purified phosphatase (1.8 mg/ml), and 0.2 ml of buffer A (total volume 1.5 ml) at 37°C for 45 min. The reaction was terminated by the addition of 0.2 ml of 0.5 M NaF. Control cytosolic reductase kinase (active) was incubated as described above for inactive reductase kinase except that the phosphatase enzyme was pretreated with 0.2 ml of 0.5 M NaF. At the end of incubation 0.2 ml of 0.5 M NaCl was added.
Unwashed microsomal suspensions (5.4 mg/ml) isolated in the presence of NaF were fractionated on a Sephadex G-25 medium column (1.5 x 5 cm) equilibrated in buffer A. Microsomes (1.28 mg) were incubated in a total volume of 1.6 ml at 37°C for 45 min with 0.9 ml of phosphoprotein phosphatase (1.8 mg/ml) containing either 0.2 ml of 0.5 M NaCl for the preparation of phosphatase-inactivated reductase kinase or 0.5 M NaF for active reductase kinase.
Partial Purification of Cytosolic Reductase Kinase Kinase from Control and Mevalonolactone-Treated Rats. Rat liver cytosols (94 ml) from control and mevalonolactone-treated rats (fluoride group) were fractionated with ammonium sulfate (0-65% saturation). The precipitate was dissolved in 5 mM TnrsHCl at pH 7.5 containing 1 mM EDTA, 50 mM NaF, 2 mM dithiothreitol, 10% glycerol, and 50 ,uM phenyl-. methylsulfonyl fluoride (buffer B). Each fraction was dialyzed in 6 liters of buffer B for 18 hr at 40C. The dialyzed fractions (85 ml, 2.81 g of protein) from each group were applied to a column of phosphocellulose (1.6 x 24.8 cm) previously equilibrated with buffer B at 40C. The columns were washed with buffer B and eluted with a gradient of buffer B (125 ml) and buffer B containing 1.5 M KCl (125 ml). Fourmilliliter fractions were collected and each fraction from two separate studies was analyzed for conductivity, protein, and reductase kinase kinase activity (see below). Fractions from each column containing reductase kinase kinase activity (conductivity 14-38 mS) were pooled and fractionated with ammonium sulfate (0-65%). The precipitate was dissolved, dialyzed in 10 mM 2-(N-morpholino)ethanesulfonic acid, pH 6.5/2 mM dithiothreitol/0.1 M sucrose (Mes buffer) and stored at -20'C. Control tubes contained no ATP. The reaction was terminated by the addition of excess EDTA and residual HMG-CoA reductase activity was determined (11) . One unit of reductase kinase kinase activity is defined as the quantity of kinase that catalyzes the activation of inactive reductase kinase and inactivation of 1 unit of HMG-CoA reductase activity in the presence of Mg ATP under standard assay conditions.
Protein was determined by the method of Bradford (12), utilizing bovine serum albumin as standard.
RESULTS
Reversible Modulation of HMG-CoA Reductase Activity by Mevalonolactone. When pooled livers from fluoride groups of control and mevalonolactone-treated rats were homogenized and microsomes were isolated in a medium containing 50 mM NaF and 10 mM EDTA, the majority of the HMGCoA reductase activity (80%) was present in the phosphorylated or inactive form (Table 1) . EDTA prevents any phosphorylation of HMG-CoA reductase and reductase kinase, 7294 Biochemistry: Beg et aL whereas addition of NaF in the medium inhibits the dephosphorylation of both HMG-CoA reductase and reductase kinase by inactivating phosphoprotein phosphatases. To obtain true expressed enzymic activity, microsomal HMGCoA reductase was incubated and assayed in the presence of NaF. However, when the NaF-prepared microsomal preparations were incubated with NaCl, higher HMG-CoA reductase activity (-20%) was observed (Table 1) . These results suggested that the NaF utilized during isolation of the microsomes did not inhibit all the endogenous microsomal phosphatase(s), allowing for some dephosphorylation of the enzyme when assayed in a NaF-free medium.
Twenty minutes after mevalonolactone administration to rats, expressed HMG-CoA reductase activity significantly declined when compared to control animals. The data presented in Table 1 are representative of three experiments. In these studies inhibition of HMG-CoA reductase activity was 31-43%. Treatment of the microsomal enzyme with partially purified rat cytosolic phosphoprotein phosphatase dephosphorylated the inactive HMG-CoA reductase enzyme and increased enzymic activity (total activity). The total enzyme activities of control and mevalonolactone-treated rats after dephosphorylation were very similar (Table 1) .
These results suggest that HMG-CoA reductase activity is subject to short-term regulation by mevalonolactone. The initial rapid effect (within 20 min) is due to inhibition of enzymic activity by increased conversion of the active form of HMG-CoA reductase to the inactive (phosphorylated) species. Treatment of phosphorylated HMG-CoA reductase with phosphoprotein phosphatase was associated with nearcomplete reactivation (dephosphorylation) of enzymic activity. In a parallel experiment HMG-CoA reductase from pooled livers of control (n = 11) and mevalonolactone-treated (n = 12) rats was purified to homogeneity by HMG-CoA affinity chromatography (4). Microsomal HMG-CoA reductase activity inhibition (31%) in mevalonolactone-treated rats was completely reversed (107%) by incubation with phosphatase. The amounts of HMG-CoA reductase protein purified under identical conditions were similar in mevalonolactone-treated rats (171.8 ,ug/100 g of liver) and control rats (170.2 ,tg/100 g of liver). In eight different experiments involving the purification of HMG-CoA reductase from cholestyramine-fed rats (n = 800) the mean (±SD) yield of purified protein was 174 ± 17 ,ug/100 g of liver.
In Vivo Modulation of Reductase Kinase. To determine whether increased inactivation (phosphorylation) of HMGCoA reductase is mediated by increased activation (phosphorylation) of reductase kinase, we quantified the reduc- Microsomes isolated from a pool of 8.5 livers in buffer A containing 50 mM NaF were washed once and the pellet was divided into two fractions, which were suspended in buffer A containing either 0.5 M NaF or 0.5 M NaCI. The microsomal suspensions were adjusted to a final protein concentration of 8 mg/ml. Microsomes in suspensions (10-40 ,ul) that contained either NaF or NaCl were assayed in duplicate for expressed HMG-CoA reductase activity in the presence of 50 mM NaF or 50 mM NaCI, respectively. HMG-CoA reductase enzymic values between duplicates varied less than 8% of the mean. Total activity was determined after incubation of the microsomes isolated in NaCI at 370C for 45 min with partially purified phosphoprotein phosphatase (1.08 mg/ml). tase kinase activities in the cytosol of control and mevalonolactone-treated rats.
Data presented in Table 2 demonstrate that the enzymic activity of reductase kinase is influenced by endogeneous phosphoprotein phosphatase(s) during homogenization of livers and isolation of cytosol. Within each group fractions isolated in the absence of a phosphatase inhibitor (NaCl group) had significantly lower activity than cytosols prepared in the presence of 50 mM NaF, which inhibit phosphatase activity (NaF group). These results also support the hypothesis that a large fraction of hepatic reductase kinase in vivo is present in the active (phosphorylated) form, whereas HMG-CoA reductase is known to exist primarily in an inactive (phosphorylated) form (13) .
Reductase kinase activity was significantly increased (2-to 3-fold) after the 20-min feeding of mevalonolactone ( Table  2 ). The increase in activity of reductase kinase was due to an increase in the degree of phosphorylation (activation). Dephosphorylation of reductase kinase preparations (Fig. 1 ) from control and mevalonolactone-treated rats was associated with total loss (inactivation) of enzymic activity. The increase in activity of reductase kinase provides a mechanism for an increased inactivation (phosphorylation) of HMGCoA reductase (Table 1) .
Regulation of Reductase Kinase Kinase by Mevalonolactone. Since activation (phosphorylation) of reductase kinase is catalyzed by reductase kinase kinase, an increase in the catalytical activity of reductase kinase kinase would provide a mechanism for the observed increase in reductase kinase activity in mevalonolactone-treated rats ( Table 2) .
The activity of reductase kinase kinase was evaluated after separation of reductase kinase activity on phosphocellulose chromatography (data not shown). Reductase kinase kinase activity eluted between 14 and 38 imS, whereas reductase kinase activity eluted at a conductivity <10 MS.
Cytosolic reductase kinase kinase activity was significantly increased in rats after mevalonolactone administration ( Fig. 1 and Table 3 ). Reductase kinase kinase activity from rats treated with mevalonolactone was increased 3-to 4-fold in the fractions obtained from phosphocellulose chromatography followed by ammonium sulfate precipitation (Table 3) . Incubation of reductase kinase kinase with phosphoprotein phosphatase did not change the kinase kinase activity, indicating that changes in this kinase activity were not due to reversible phosphorylation (data not shown).
The ability of partially purified reductase kinase kinase (ammonium sulfate fraction) to modulate the activity of reductase kinase is illustrated in Fig. 1 . The ability of partially purified reductase kinase kinase fractions to catalyze the phosphorylation (activation) of phosphatase-inactivated reductase kinase from control and mevalonolactone-treated rats was 22% and 80%, respectively. Incubation of inactive reductase kinase with Mg ATP and partially purified reduc- Aliquots of cytosols prepared in NaCl or NaF from control and mevalonolactone-treated rats were assayed for reductase kinase activity in the presence of 8 mM Mg2" and 1.3 mM ATP.
Biochemistry: Beg et aL the activation (dephosphorylation) of HMG-CoA reductase was significantly higher in the control rats than in the mevalonolactone-treated rats (Table 4 ). The inhibition of the phosphoprotein phosphatase would favor the in vivo phosphorylated state of both HMG-CoA reductase and reductase kinase.
DISCUSSION
Studies over the last few years have established several mechanisms for the regulation of the activity of HMG-CoA reductase and the production of mevalonate. Of particular interest has been the elucidation of a rapid short-term mechanism for regulation of the enzymic activity of HMG-CoA reductase by a bicyclic cascade system. The bicyclic cascade system has been identified in rats (2, 3, 8) and humans (14) and involves the reversible phosphorylation of HMGCoA reductase and reductase kinase. HMG-CoA reductase is active in the dephosphorylated form, whereas the phosphorylated form of reductase kinase is the active species.
The kinase that catalyzes the phosphorylation of reductase kinase, reductase kinase kinase, is cyclic nucleotide independent. In addition to modulation of the enzymic activity of HMG-CoA reductase by reversible phosphorylation, there is long-term regulation of HMG-CoA reductase activity by alterations in both biosynthesis and degradation (15) .
In the present report, we have investigated the mechanism for the inhibition of HMG-CoA reductase activity by mevalonolactone. Mevalonate serves as a substrate for the biosynthesis of cholesterol, ubiquinones, dolichols, and isopentenyl-tRNA, necessitating a precise control of the cellular levels of mevalonate.
The combined results obtained in the present study indicate that the mevalonolactone-mediated in vivo inactivation of HMG-CoA reductase was achieved by two mechanisms: (i) Increased activity of reductase kinase kinase; the increase in activity of reductase kinase kinase increased the phosphorylation and enzymic activity of reductase kinase, which in turn decreased the activity of HMG-CoA reductase by increasing the percentage of HMG-CoA reductase in the phos- 1.85 98 17 The microsomal suspension isolated from control rats in the presence of NaF was used for the dephosphorylation of HMG-CoA reductase by utilizing different concentrations of partially purified phosphatase from cytosols of normal and mevalonolactone-treated rats (chloride group). Phosphorylated microsomal HMG-CoA reductase (118 ,g) was incubated at 37°C (30 min) in buffer A (250 ,ul) containing the indicated quantities of phosphatase from each group. HMG-CoA reductase activity was determined at the end of the incubation (11) . *The mean values ± SD for control and mevalonolactone-treated rats were 27 ± 3.6%, and 16 ± 0.96%, respectively.
tExpressed HMG-CoA reductase activity was quantitated in the absence of phosphatase from phosphorylated microsomal suspensions (see above).
Proc. Nati. The dephosphorylation and activation of inactive (phosphorylated) HMG-CoA reductase is decreased due to the decrease in activity of reductase phosphatase. These combined effects result in a decrease of HMG-CoA reductase activity due to an increase in steady-state level of the phosphorylated enzyme, leading to a decrease in mevalonic acid and cholesterol biosynthesis. phorylated form (Fig. 2A ). These results demonstrate that the activity of reductase kinase kinase is modulated in vivo, providing a mechanism for regulation of the activities of both reductase kinase and HMG-CoA reductase. (it) Decreased activity of phosphoprotein phosphatase(s); a decrease in the activity of the phosphatase(s) decreased the dephosphorylation of both reductase kinase and HMG-CoA reductase. The increase in the steady-state level of the phosphorylated forms of both reductase kinase and HMG-CoA reductase would result in a net decline in HMG-CoA reductase activity and mevalonate formation (Fig. 2B) .
The mechanism(s) by which mevalonolactone mediated the inhibition of phosphoprotein phosphatase activity remains to be elucidated. One possible route of phosphatase inhibition may involve activation of the phosphatase inhibitor 1, or 2, or both under the influence of mevalonolactone. In other tissues, inhibitors 1 and 2 are known to modulate the catalytic activity of phosphoprotein phosphatase(s) (16) (17) (18) (19) .
Addition of mevalonolactone (1-10 mM) in vitro to the incubation medium did not effect the activities of HMG-CoA reductase, reductase kinase, reductase kinase kinase, and phosphoprotein phosphatase, suggesting that in vivo mevalonolactone did not directly effect the activities of these enzymes (data not shown). Failure of mevalonolactone to activate reductase kinase kinase in vitro indicates that a metabolic product of mevalonolactone may be involved in inducing the changes in reductase kinase kinase activity, thus providing a mechanism for regulating the activities of both reductase kinase and HMG-CoA reductase.
The present studies underscore the complex regulation of the enzymic activity of HMG-CoA reductase. The simultaneous modulation of the activities of both reductase kinase and reductase kinase kinase as well as the activity of phosphoprotein phosphatase provides an exceptionally effective mechanism for the regulation of the cellular level of activeinactive HMG-CoA reductase. Additional studies will be required to determine other effectors that regulate the extent of phosphorylation-dephosphorylation of HMG-CoA reductase.
